MIRA 8-K: SEC filing
MIRA Pharmaceuticals
Filed with the SEC on · accession 0001493152-26-052331
MIRA filed a 8-K (current report) with the SEC on Nov 16, 2026. MIRA Pharmaceuticals announced new preclinical receptor selectivity findings for MIRA-55, its investigational oral non-opioid drug candidate for inflammatory pain, showing greater than 500-fold separation from opioid receptor interactions and no substantial COX-1/COX-2 inhibition.
Summary of the filing
MIRA Pharmaceuticals announced new preclinical receptor selectivity findings for MIRA-55, its investigational oral non-opioid drug candidate for inflammatory pain, showing greater than 500-fold separation from opioid receptor interactions and no substantial COX-1/COX-2 inhibition. The company is advancing MIRA-55 through IND-enabling activities with a target IND submission in the first half of 2027.
Key details
✦ Ask GOAX AI about this filing — what it means for MIRA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for MIRA?
Click hereFrequently asked questions
What did MIRA file with the SEC on Nov 16, 2026?
MIRA filed a 8-K (SEC filing). MIRA Pharmaceuticals announced new preclinical receptor selectivity findings for MIRA-55, its investigational oral non-opioid drug candidate for inflammatory pain, showing greater than 500-fold separation from opioid receptor interactions and no substantial COX-1/COX-2 inhibition. The company is advancing MIRA-55 through IND-enabling activities with a target IND submission in the first half of 2027.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other MIRA SEC filings
- 8-K · SEC filingOct 28, 2026
- 8-K · SEC filingOct 22, 2026
- 8-K · Fda approvalSep 17, 2026
- 8-K · Board changeSep 16, 2026
- 8-K · Fda approvalSep 1, 2026
- 10-Q · SEC filingAug 12, 2026
- 8-K · Fda approvalAug 6, 2026
- 8-K · Delisting noticeJul 31, 2026
- DEF 14A · Board changeJul 28, 2026
- 8-K · Fda approvalJul 10, 2026
Get alerts when MIRA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days